The analyses and visuals on this site are for informational purposes only and do not constitute investment advice.

© 2026 Datafin Financial Data Analysis Systems. All rights reserved. · v2.0

Privacy PolicyTerms of UseCookie Policy

TEVA FINANCIAL STATEMENTS

Teva Pharma Industries Ltd ADR — balance sheet, income statement and cash flow trends

TEVATeva Pharma Industries Ltd ADR

🇺🇸 USA · US · Healthcare · Drug Manufacturers - Specialty & Generic

Value itDuel
PriceFinancialsPeers

Income Statement

Quarterly progression — trailing-twelve-month values
RevenueNet Income
010 B202120222023202420252026

Profit Funnel

Q1 2026 · TTM
Revenue17.3 B $Gross Profit9 B $ · 52%Operating Income2.3 B $ · 13%Pre-tax Income1.4 B $ · 8%Net Income1.6 B $ · 9%

Percentages are relative to revenue.

Key Figures

YoY change
Revenue17.3 B $+4.4%
Gross Profit9 B $+10.6%
Operating Income2.3 B $+427.4%
EBITDA3.3 B $+27.3%
Net Income1.6 B $—

Peer Comparison· Drug Manufacturers - Specialty & Generic

CompanyRev. GrowthGross MarginEBITDA MarginNet Margin
TEVA4.4%52.1%18.8%9.0%
Industry median7.5%60.6%18.2%4.0%

Balance Sheet

Quarterly period-end values
Total AssetsTotal LiabilitiesEquity
020 B40 B202120222023202420252026

Capital Structure

Q1 2026
Total Assets40 B
  • Equity8.2 B $21%
  • Current Liabilities13.5 B $34%
  • Long-term Liabilities18.3 B $46%

Key Figures

YoY change
Total Assets40 B $+4.2%
Total Liabilities31.8 B $-1.1%
Total Equity8.2 B $+31.4%
Cash & ST Investments3.7 B $+120.5%
Total Debt16.9 B $-0.2%
Net Debt13.2 B $-13.6%

Peer Comparison· Drug Manufacturers - Specialty & Generic

CompanyCurrent RatioDebt/EquityNetDebt/EBITDAEquity/Assets
TEVA1.01205.5%4.0320.5%
Industry median2.2246.3%1.2445.7%

Cash Flow Statement

Quarterly progression — trailing-twelve-month values
Operating Cash FlowCapital ExpendituresFree Cash Flow
01 B202120222023202420252026

Cash Flow Bridge

Q1 2026 · TTM
01 B2 B1.7 B $Operating765 M $Investing-394 M $Financing2.1 B $Net Change

Key Figures

YoY change
Operating Cash Flow1.7 B $+35.4%
Capital Expenditures542 M $+8.2%
Free Cash Flow1.2 B $+53.2%
Dividends Paid——

Peer Comparison· Drug Manufacturers - Specialty & Generic

CompanyCF MarginFCF MarginCapEx RatioCF/Net Income
TEVA9.9%6.8%3.1%109.6%
Industry median15.2%11.6%2.5%84.3%

Amounts are in the company’s reporting currency. Peer comparison tables use ratio-based metrics so currency differences do not distort the picture.

Go deeper on TEVA

Run a DCF valuation

Full DCF model with editable assumptions

Start a head-to-head duel

Compare two stocks metric by metric

Filter in the stock screener

Build your own universe with 400+ metrics

Data on this page refreshes once per day. This content is for informational purposes only and is not investment advice.